Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1986-06-26
1989-05-02
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 68, 514253, 5142282, 5142328, 544 584, 544 61, 544125, 544361, A61K 3144, A61K 3154, C07D45712, C07D41714
Patent
active
048268526
ABSTRACT:
Ergolinyl compounds which are nitrogen-substituted in the 8-position and have Formula (I) ##STR1## and physiologically compatible salts thereof, wherein (a) R.sup.1 is hydrogen, the 8-substituent can be in the .alpha.- or .beta.-position and ##STR2## represents a single or a double bond, R.sup.2 is hydrogen, C.sub.1-4 -alkyl or C.sub.1-7 -acyl,
REFERENCES:
patent: 2533698 (1950-12-01), Stoll
patent: 2864822 (1958-12-01), Fornefeld et al.
patent: 3717640 (1973-02-01), Acari
patent: 4348391 (1982-09-01), Fehr
patent: 4348392 (1982-09-01), Fehr
patent: 4500712 (1985-02-01), Bernardi et al.
patent: 4740509 (1988-04-01), Sauer et al.
Wachtel et al., Life Science, vol. 32, pp. 421-432 (1983).
Eder Ulrich
Haffer Gregor
Sauer Gerhard
Schneider Herbert
Wachtel Helmut
Gerstl Robert
Schering Aktiengesellschaft
Shen Cecilia A.
LandOfFree
Novel ergolinyl compounds nitrogen-substituted in the 8-position does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel ergolinyl compounds nitrogen-substituted in the 8-position, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel ergolinyl compounds nitrogen-substituted in the 8-position will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-585221